Biotie Gears Up For New Pivotal Trial Of Tozadenant In Parkinson’s
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
With the goal of introducing the first adenosine A2a antagonist for Parkinson’s disease in North America and Europe, Biotie plans to start a Phase III study of tozadenant in almost 900 Parkinson’s patients this summer.
You may also be interested in...
Merck Halts Preladenant Development In Parkinson’s Following Phase III Failures
Company says it will not pursue regulatory filings for the adenosine-2a receptor antagonist because studies in moderate-to-severe and early-stage disease failed to show sufficient evidence of efficacy.
UCB Exercises Tozadenant Option But Asks Biotie To Move It To Phase III
Biotie Therapies gets $20 million as UCB exercises its option on the investigational Parkinson's disease therapy tozadenant and asks the Finnish biotech to continue its clinical development of the product into Phase III.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.